NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus

Active Not RecruitingN/A

Sponsor: AstraZeneca

Conditions: Lupus Erythematosus, Systemic

Interventions: Anifrolumab

Countries: Poland

The Polish multicentre observational (non-interventional) study aiming to collect data on the characteristic of patients with systemic lupus erythematosus and clinical outcomes of anifrolumab administered in the scope of routine clinical practice.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

1. Adult (aged ≥18 years old) patients with SLE who received anifrolumab treatment in the frames of NDP in Poland.
2. Patients willing to participate in the study and signed Informed Consent Form (ICF).

Exclusion Criteria:

1. Those who participated in anifrolumab clinical trial in the past, and/or those who participated/plans to participate in clinical trial on/after the date of first anifrolumab infusion through NDP.
2. Cognitive incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.

Locations (11)

Bydgoszcz, Poland
Bytom, Poland
Gdansk, Poland
Katowice, Poland
Krakow, Poland
Lodz, Poland
Lublin, Poland
Poznan, Poland
Rzeszów, Poland
Warsaw, Poland
Wroclaw, Poland